Advertisement
EBS vs QNTM
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EBS is a StrongBuy and QNTM is a StrongBuy.
EBS in +4.27% Uptrend, growing for three consecutive days on November 09, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where EBS advanced for three days, in 214 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 60 cases where EBS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EBS as a result. In 81 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for EBS turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 40 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
EBS moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for EBS crossed bearishly below the 50-day moving average on November 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 17 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EBS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for EBS entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.910) is normal, around the industry mean (6.379). P/E Ratio (-1.782) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.160) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.493) is also within normal values, averaging (183.387).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. EBS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EBS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
QNTM in +5.17% Uptrend, rising for three consecutive days on October 29, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where QNTM advanced for three days, in 198 of 233 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for QNTM's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for QNTM just turned positive on October 30, 2026. Looking at past instances where QNTM's MACD turned positive, the stock continued to rise in 31 of 38 cases over the following month. The odds of a continued upward trend are 82%.
QNTM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on QNTM as a result. In 60 of 65 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The 10-day moving average for QNTM crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QNTM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for QNTM entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.142) is normal, around the industry mean (3.498). P/E Ratio (-0.469) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. QNTM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QNTM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
EBS | QNTM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 62 | 53 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 39 Fair valued | 71 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 100 | |
PRICE GROWTH RATING 1..100 | 60 | 88 | |
P/E GROWTH RATING 1..100 | 98 | 14 | |
SEASONALITY SCORE 1..100 | 50 | 2 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EBS's Valuation (39) in the Biotechnology industry is in the same range as QNTM (71) in the null industry. This means that EBS’s stock grew similarly to QNTM’s over the last 12 months.
EBS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as QNTM (100) in the null industry. This means that EBS’s stock grew similarly to QNTM’s over the last 12 months.
EBS's SMR Rating (97) in the Biotechnology industry is in the same range as QNTM (100) in the null industry. This means that EBS’s stock grew similarly to QNTM’s over the last 12 months.
EBS's Price Growth Rating (60) in the Biotechnology industry is in the same range as QNTM (88) in the null industry. This means that EBS’s stock grew similarly to QNTM’s over the last 12 months.
QNTM's P/E Growth Rating (14) in the null industry is significantly better than the same rating for EBS (98) in the Biotechnology industry. This means that QNTM’s stock grew significantly faster than EBS’s over the last 12 months.
| EBS | QNTM | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 71% |
| Stochastic ODDS (%) | 2 days ago 78% | 2 days ago 82% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 83% | 2 days ago 82% |
| TrendWeek ODDS (%) | 2 days ago 88% | 2 days ago 89% |
| TrendMonth ODDS (%) | 2 days ago 87% | 2 days ago 89% |
| Advances ODDS (%) | 3 days ago 80% | 14 days ago 85% |
| Declines ODDS (%) | 7 days ago 86% | 6 days ago 90% |
| BollingerBands ODDS (%) | N/A | 2 days ago 85% |
| Aroon ODDS (%) | 2 days ago 87% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EBS’s FA Score shows that 0 FA rating(s) are green while QNTM’s FA Score has 1 green FA rating(s).
- EBS’s FA Score: 0 green, 5 red.
- QNTM’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EBS’s TA Score shows that 2 TA indicator(s) are bullish while QNTM’s TA Score has 5 bullish TA indicator(s).
- EBS’s TA Score: 2 bullish, 6 bearish.
- QNTM’s TA Score: 5 bullish, 4 bearish.
Price Growth
EBS (@Pharmaceuticals: Generic) experienced а -3.20% price change this week, while QNTM (@Biotechnology) price change was -8.60% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.20%. For the same industry, the average monthly price growth was -6.54%, and the average quarterly price growth was +10.31%.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
EBS is expected to report earnings on Mar 03, 2027.
QNTM is expected to report earnings on Nov 13, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-0.20% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
EBS and
Correlation & Price change
A.I.dvisor indicates that over the last year, EBS has been loosely correlated with AMPH. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if EBS jumps, then AMPH could also see price increases.
| Ticker / NAME | Correlation To EBS | 1D Price Change % | ||
|---|---|---|---|---|
| EBS | 100% | -0.82% | ||
| AMPH - EBS | 41% Loosely correlated | -1.09% | ||
| SIGA - EBS | 40% Loosely correlated | -3.99% | ||
| COLL - EBS | 40% Loosely correlated | -0.97% | ||
| XERS - EBS | 33% Loosely correlated | -0.19% | ||
| VTRS - EBS | 32% Poorly correlated | +1.76% | ||
More | ||||
QNTM and
Correlation & Price change
A.I.dvisor indicates that over the last year, QNTM has been loosely correlated with TNXP. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if QNTM jumps, then TNXP could also see price increases.
| Ticker / NAME | Correlation To QNTM | 1D Price Change % | ||
|---|---|---|---|---|
| QNTM | 100% | -9.42% | ||
| TNXP - QNTM | 35% Loosely correlated | -8.69% | ||
| AZTR - QNTM | 29% Poorly correlated | -6.83% | ||
| ATHE - QNTM | 27% Poorly correlated | -4.53% | ||
| CPIX - QNTM | 26% Poorly correlated | -1.30% | ||
| EBS - QNTM | 24% Poorly correlated | -0.82% | ||
More | ||||